Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 148

1.

HIF-1α is overexpressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia.

Griggio V, Vitale C, Todaro M, Riganti C, Kopecka J, Salvetti C, Bomben R, Dal Bo M, Magliulo D, Rossi D, Pozzato G, Bonello L, Marchetti M, Omedè P, Kodipad AA, Laurenti L, Del Poeta G, Mauro FR, Bernardi R, Zenz T, Gattei V, Gaidano G, Foà R, Massaia M, Boccadoro M, Coscia M.

Haematologica. 2019 Jul 9. pii: haematol.2019.217430. doi: 10.3324/haematol.2019.217430. [Epub ahead of print]

2.

A Position Paper on IgM-Enriched Intravenous Immunoglobulin Adjunctive Therapy in Severe Acute Bacterial Infections: The TO-PIRO SCORE Proposal.

De Rosa FG, Corcione S, Tascini C, Pasero D, Rocchetti A, Massaia M, Berlot G, Solidoro P, Girardis M.

New Microbiol. 2019 Jun 3;41(2). [Epub ahead of print]

3.

Mitochondrial metabolism: Inducer or therapeutic target in tumor immune-resistance?

Kopecka J, Gazzano E, Castella B, Salaroglio IC, Mungo E, Massaia M, Riganti C.

Semin Cell Dev Biol. 2019 May 18. pii: S1084-9521(18)30164-2. doi: 10.1016/j.semcdb.2019.05.008. [Epub ahead of print] Review.

PMID:
31100351
4.

Increasing intratumor C/EBP-β LIP and nitric oxide levels overcome resistance to doxorubicin in triple negative breast cancer.

Salaroglio IC, Gazzano E, Abdullrahman A, Mungo E, Castella B, Abd-Elrahman GEFA, Massaia M, Donadelli M, Rubinstein M, Riganti C, Kopecka J.

J Exp Clin Cancer Res. 2018 Nov 27;37(1):286. doi: 10.1186/s13046-018-0967-0.

5.

Vγ9Vδ2 T Cells as Strategic Weapons to Improve the Potency of Immune Checkpoint Blockade and Immune Interventions in Human Myeloma.

Castella B, Melaccio A, Foglietta M, Riganti C, Massaia M.

Front Oncol. 2018 Nov 6;8:508. doi: 10.3389/fonc.2018.00508. eCollection 2018. Review.

6.

Microvesicles released from multiple myeloma cells are equipped with ectoenzymes belonging to canonical and non-canonical adenosinergic pathways and produce adenosine from ATP and NAD.

Morandi F, Marimpietri D, Horenstein AL, Bolzoni M, Toscani D, Costa F, Castella B, Faini AC, Massaia M, Pistoia V, Giuliani N, Malavasi F.

Oncoimmunology. 2018 May 7;7(8):e1458809. doi: 10.1080/2162402X.2018.1458809. eCollection 2018.

7.

Vγ9Vδ2 T Cells in the Bone Marrow of Myeloma Patients: A Paradigm of Microenvironment-Induced Immune Suppression.

Castella B, Foglietta M, Riganti C, Massaia M.

Front Immunol. 2018 Jun 25;9:1492. doi: 10.3389/fimmu.2018.01492. eCollection 2018. Review.

8.

ABCA1, apoA-I, and BTN3A1: A Legitimate Ménage à Trois in Dendritic Cells.

Riganti C, Castella B, Massaia M.

Front Immunol. 2018 Jun 8;9:1246. doi: 10.3389/fimmu.2018.01246. eCollection 2018. Review.

9.

Tailoring CD19xCD3-DART exposure enhances T-cells to eradication of B-cell neoplasms.

Circosta P, Elia AR, Landra I, Machiorlatti R, Todaro M, Aliberti S, Brusa D, Deaglio S, Chiaretti S, Bruna R, Gottardi D, Massaia M, Giacomo FD, Guarini AR, Foà R, Kyriakides PW, Bareja R, Elemento O, Chichili GR, Monteleone E, Moore PA, Johnson S, Bonvini E, Cignetti A, Inghirami G.

Oncoimmunology. 2018 Feb 8;7(4):e1341032. doi: 10.1080/2162402X.2017.1341032. eCollection 2018.

10.

Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding.

Boriani G, Corradini P, Cuneo A, Falanga A, Foà R, Gaidano G, Ghia PP, Martelli M, Marasca R, Massaia M, Mauro FR, Minotti G, Molica S, Montillo M, Pinto A, Tedeschi A, Vitolo U, Zinzani PL.

Hematol Oncol. 2018 Oct;36(4):624-632. doi: 10.1002/hon.2503. Epub 2018 Mar 7. Review.

PMID:
29512173
11.

A Score-Based Approach to 18F-FDG PET Images as a Tool to Describe Metabolic Predictors of Myocardial Doxorubicin Susceptibility.

Bauckneht M, Morbelli S, Fiz F, Ferrarazzo G, Piva R, Nieri A, Sarocchi M, Spallarossa P, Canepari ME, Arboscello E, Bellodi A, Massaia M, Gallamini A, Bruzzi P, Marini C, Sambuceti G.

Diagnostics (Basel). 2017 Oct 26;7(4). pii: E57. doi: 10.3390/diagnostics7040057.

12.

Chlorambucil plus rituximab as front-line therapy for elderly and/or unfit chronic lymphocytic leukemia patients: correlation with biologically-based risk stratification.

Laurenti L, Innocenti I, Autore F, Ciolli S, Mauro FR, Mannina D, Del Poeta G, D'Arena G, Massaia M, Coscia M, Molica S, Pozzato G, Efremov DG, Vannata B, Marasca R, Galieni P, Cuneo A, Orlando S, Piciocchi A, Boncompagni R, Vincelli D, Liberati AM, Russo F, Foá R.

Haematologica. 2017 Sep;102(9):e352-e355. doi: 10.3324/haematol.2016.156901. Epub 2017 Jun 8. No abstract available.

13.

The ATP-binding cassette transporter A1 regulates phosphoantigen release and Vγ9Vδ2 T cell activation by dendritic cells.

Castella B, Kopecka J, Sciancalepore P, Mandili G, Foglietta M, Mitro N, Caruso D, Novelli F, Riganti C, Massaia M.

Nat Commun. 2017 Jun 5;8:15663. doi: 10.1038/ncomms15663.

14.

Progressive telomere shortening is part of the natural history of chronic lymphocytic leukaemia and impacts clinical outcome: evidences from long term follow-up.

Ghione P, Genuardi E, Rossi D, Drandi D, Mantoan B, Barbero D, Bernocco E, Monitillo L, Cerri M, Ruggeri M, Omede P, Deambrogi C, De Paoli L, Passera R, Coscia M, Cavallo F, Massaia M, Boccadoro M, Gaidano G, Ladetto M, Ferrero S.

Br J Haematol. 2018 Jun;181(5):693-695. doi: 10.1111/bjh.14681. Epub 2017 Apr 2. No abstract available.

PMID:
28369711
15.

Humoral immune responses toward tumor-derived antigens in previously untreated patients with chronic lymphocytic leukemia.

Griggio V, Mandili G, Vitale C, Capello M, Macor P, Serra S, Castella B, Peola S, Foglietta M, Drandi D, Omedé P, Sblattero D, Cappello P, Chiarle R, Deaglio S, Boccadoro M, Novelli F, Massaia M, Coscia M.

Oncotarget. 2017 Jan 10;8(2):3274-3288. doi: 10.18632/oncotarget.13712.

16.

Stem cell transplantation in multiple myeloma and other plasma cell disorders (report from an EBMT preceptorship meeting).

Bruno B, Auner HW, Gahrton G, Garderet L, Festuccia M, Ladetto M, Lemoli RM, Massaia M, Morris C, Palumbo A, Schönland S, Boccadoro M, Kröger N.

Leuk Lymphoma. 2016;57(6):1256-68. doi: 10.3109/10428194.2015.1131278. Epub 2016 Jan 6. Review.

17.

Anergic bone marrow Vγ9Vδ2 T cells as early and long-lasting markers of PD-1-targetable microenvironment-induced immune suppression in human myeloma.

Castella B, Foglietta M, Sciancalepore P, Rigoni M, Coscia M, Griggio V, Vitale C, Ferracini R, Saraci E, Omedé P, Riganti C, Palumbo A, Boccadoro M, Massaia M.

Oncoimmunology. 2015 May 26;4(11):e1047580. eCollection 2015 Nov.

18.

A phase II multi-center trial of pentostatin plus cyclophosphamide with ofatumumab in older previously untreated chronic lymphocytic leukemia patients.

Tedeschi A, Rossi D, Motta M, Quaresmini G, Rossi M, Coscia M, Anastasia A, Rossini F, Cortelezzi A, Nador G, Scarfò L, Cairoli R, Frustaci AM, Dalceggio D, Picardi P, De Paoli L, Orlandi E, Rambaldi A, Massaia M, Gaidano G, Montillo M; Rete Ematologica Lombarda–CLL Workgroup.

Haematologica. 2015 Dec;100(12):e501-4. doi: 10.3324/haematol.2015.132035. Epub 2015 Aug 20. No abstract available.

19.

Simvastatin and downstream inhibitors circumvent constitutive and stromal cell-induced resistance to doxorubicin in IGHV unmutated CLL cells.

Rigoni M, Riganti C, Vitale C, Griggio V, Campia I, Robino M, Foglietta M, Castella B, Sciancalepore P, Buondonno I, Drandi D, Ladetto M, Boccadoro M, Massaia M, Coscia M.

Oncotarget. 2015 Oct 6;6(30):29833-46. doi: 10.18632/oncotarget.4006.

20.

Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia.

Rossi D, Terzi-di-Bergamo L, De Paoli L, Cerri M, Ghilardi G, Chiarenza A, Bulian P, Visco C, Mauro FR, Morabito F, Cortelezzi A, Zaja F, Forconi F, Laurenti L, Del Giudice I, Gentile M, Vincelli I, Motta M, Coscia M, Rigolin GM, Tedeschi A, Neri A, Marasca R, Perbellini O, Moreno C, Del Poeta G, Massaia M, Zinzani PL, Montillo M, Cuneo A, Gattei V, Foà R, Gaidano G.

Blood. 2015 Oct 15;126(16):1921-4. doi: 10.1182/blood-2015-05-647925. Epub 2015 Aug 14.

21.

Chicago 2014--30 years of γδ T cells.

Bonneville M, Chen ZW, Déchanet-Merville J, Eberl M, Fournié JJ, Jameson JM, Lopez RD, Massaia M, Silva-Santos B.

Cell Immunol. 2015 Jul;296(1):3-9. doi: 10.1016/j.cellimm.2014.11.001. Epub 2014 Nov 8.

22.

The bone marrow of myeloma patients is steadily inhabited by a normal-sized pool of functional regulatory T cells irrespectiveof the disease status.

Foglietta M, Castella B, Mariani S, Coscia M, Godio L, Ferracini R, Ruggeri M, Muccio V, Omedé P, Palumbo A, Boccadoro M, Massaia M.

Haematologica. 2014 Oct;99(10):1605-10. doi: 10.3324/haematol.2014.105866. Epub 2014 Jun 27.

23.

Bendamustine and subcutaneous alemtuzumab combination is an effective treatment in relapsed/refractory chronic lymphocytic leukemia patients.

Montillo M, Tedeschi A, Gaidano G, Coscia M, Petrizzi VB, Orlandi E, Cascavilla N, Ghia P, Motta M, Gallamini A, Frustaci AM, Rossi D, De Paoli L, Nichelatti M, Morra E, Massaia M.

Haematologica. 2014 Sep;99(9):e159-61. doi: 10.3324/haematol.2014.106740. Epub 2014 Jun 27. No abstract available.

24.

Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients.

Foà R, Del Giudice I, Cuneo A, Del Poeta G, Ciolli S, Di Raimondo F, Lauria F, Cencini E, Rigolin GM, Cortelezzi A, Nobile F, Callea V, Brugiatelli M, Massaia M, Molica S, Trentin L, Rizzi R, Specchia G, Di Serio F, Orsucci L, Ambrosetti A, Montillo M, Zinzani PL, Ferrara F, Morabito F, Mura MA, Soriani S, Peragine N, Tavolaro S, Bonina S, Marinelli M, De Propris MS, Starza ID, Piciocchi A, Alietti A, Runggaldier EJ, Gamba E, Mauro FR, Chiaretti S, Guarini A.

Am J Hematol. 2014 May;89(5):480-6. doi: 10.1002/ajh.23668. Epub 2014 Feb 18.

26.

Clinicopathologic spectrum of cutaneous diseases in patients with hematologic malignancies with or without allogeneic bone marrow transplantation: an observational cohort study in 101 patients.

Quaglino P, Nardò T, Fierro MT, Massaia M, Orsucci L, Fava P, Marenco F, Marra E, Savoia P, Vitolo U, Boccadoro M, Bernengo M.

G Ital Dermatol Venereol. 2013 Oct;148(5):453-63.

27.

Anti-CD38 antibody therapy: windows of opportunity yielded by the functional characteristics of the target molecule.

Chillemi A, Zaccarello G, Quarona V, Ferracin M, Ghimenti C, Massaia M, Horenstein AL, Malavasi F.

Mol Med. 2013 May 20;19:99-108. doi: 10.2119/molmed.2013.00009. Review.

28.

Zoledronic acid restores doxorubicin chemosensitivity and immunogenic cell death in multidrug-resistant human cancer cells.

Riganti C, Castella B, Kopecka J, Campia I, Coscia M, Pescarmona G, Bosia A, Ghigo D, Massaia M.

PLoS One. 2013 Apr 12;8(4):e60975. doi: 10.1371/journal.pone.0060975. Print 2013.

29.

Dysfunctional Vγ9Vδ2 T cells are negative prognosticators and markers of dysregulated mevalonate pathway activity in chronic lymphocytic leukemia cells.

Coscia M, Vitale C, Peola S, Foglietta M, Rigoni M, Griggio V, Castella B, Angelini D, Chiaretti S, Riganti C, Guarini A, Drandi D, Ladetto M, Bosia A, Foà R, Battistini L, Boccadoro M, Fournié JJ, Massaia M.

Blood. 2012 Oct 18;120(16):3271-9. doi: 10.1182/blood-2012-03-417519. Epub 2012 Aug 29.

30.

Human γδ T-cell responses in infection and immunotherapy: common mechanisms, common mediators?

Riganti C, Massaia M, Davey MS, Eberl M.

Eur J Immunol. 2012 Jul;42(7):1668-76. doi: 10.1002/eji.201242492. Review.

31.

SIE, SIES, GITMO evidence-based guidelines on novel agents (thalidomide, bortezomib, and lenalidomide) in the treatment of multiple myeloma.

Barosi G, Merlini G, Billio A, Boccadoro M, Corradini P, Marchetti M, Massaia M, Tosi P, Palumbo A, Cavo M, Tura S.

Ann Hematol. 2012 Jun;91(6):875-88. doi: 10.1007/s00277-012-1445-y. Epub 2012 Apr 4. Review.

PMID:
22476884
32.

Immune modulation by zoledronic acid in human myeloma: an advantageous cross-talk between Vγ9Vδ2 T cells, αβ CD8+ T cells, regulatory T cells, and dendritic cells.

Castella B, Riganti C, Fiore F, Pantaleoni F, Canepari ME, Peola S, Foglietta M, Palumbo A, Bosia A, Coscia M, Boccadoro M, Massaia M.

J Immunol. 2011 Aug 15;187(4):1578-90. doi: 10.4049/jimmunol.1002514. Epub 2011 Jul 13.

33.

Vγ9Vδ2 T cell-based immunotherapy in hematological malignancies: from bench to bedside.

Castella B, Vitale C, Coscia M, Massaia M.

Cell Mol Life Sci. 2011 Jul;68(14):2419-32. doi: 10.1007/s00018-011-0704-8. Epub 2011 May 17. Review.

PMID:
21584812
34.

Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma.

Giaccone L, Storer B, Patriarca F, Rotta M, Sorasio R, Allione B, Carnevale-Schianca F, Festuccia M, Brunello L, Omedè P, Bringhen S, Aglietta M, Levis A, Mordini N, Gallamini A, Fanin R, Massaia M, Palumbo A, Ciccone G, Storb R, Gooley TA, Boccadoro M, Bruno B.

Blood. 2011 Jun 16;117(24):6721-7. doi: 10.1182/blood-2011-03-339945. Epub 2011 Apr 13.

35.

IGHV unmutated CLL B cells are more prone to spontaneous apoptosis and subject to environmental prosurvival signals than mutated CLL B cells.

Coscia M, Pantaleoni F, Riganti C, Vitale C, Rigoni M, Peola S, Castella B, Foglietta M, Griggio V, Drandi D, Ladetto M, Bosia A, Boccadoro M, Massaia M.

Leukemia. 2011 May;25(5):828-37. doi: 10.1038/leu.2011.12. Epub 2011 Mar 4.

36.

Malnutrition in an elderly demented population living at home.

Isaia G, Mondino S, Germinara C, Cappa G, Aimonino-Ricauda N, Bo M, Isaia GC, Nobili G, Massaia M.

Arch Gerontol Geriatr. 2011 Nov-Dec;53(3):249-51. doi: 10.1016/j.archger.2010.12.015. Epub 2011 Jan 13.

PMID:
21236503
37.

Stress in professional care-givers working with patients with dementia: a hypothesis-generating study.

Isaia G, Astengo M, Isaia GC, Bo M, Cappa G, Mondino S, Nobili G, Dimonte V, Nkouka LE, Massaia M.

Aging Clin Exp Res. 2011 Oct-Dec;23(5-6):463-9. doi: 10.3275/7412. Epub 2010 Dec 15.

38.

Nitrogen-containing bisphosphonates and cancer immunotherapy.

Clézardin P, Massaia M.

Curr Pharm Des. 2010;16(27):3007-2014. Review.

PMID:
20722623
39.

Early CPAP prevents evolution of acute lung injury in patients with hematologic malignancy.

Squadrone V, Massaia M, Bruno B, Marmont F, Falda M, Bagna C, Bertone S, Filippini C, Slutsky AS, Vitolo U, Boccadoro M, Ranieri VM.

Intensive Care Med. 2010 Oct;36(10):1666-74. doi: 10.1007/s00134-010-1934-1. Epub 2010 Jun 9.

PMID:
20533022
40.

Melphalan 200 mg/m(2) versus melphalan 100 mg/m(2) in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study.

Palumbo A, Bringhen S, Bruno B, Falcone AP, Liberati AM, Grasso M, Ria R, Pisani F, Cangialosi C, Caravita T, Levi A, Meloni G, Nozza A, Pregno P, Gabbas A, Callea V, Rizzo M, Annino L, De Stefano V, Musto P, Baldi I, Cavallo F, Petrucci MT, Massaia M, Boccadoro M.

Blood. 2010 Mar 11;115(10):1873-9. doi: 10.1182/blood-2009-09-241737. Epub 2009 Dec 1. Erratum in: Blood. 2010 Sep 23;116(12):2195.

41.

Costs of the in-home patients affected by dementia.

Isaia G, M Bo, Nobili G, Cappa G, Mondino S, Pilon S, Massaia M.

Arch Gerontol Geriatr. 2009;49 Suppl 1:147-51. doi: 10.1016/j.archger.2009.09.024.

42.

Zoledronic acid repolarizes tumour-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway.

Coscia M, Quaglino E, Iezzi M, Curcio C, Pantaleoni F, Riganti C, Holen I, Mönkkönen H, Boccadoro M, Forni G, Musiani P, Bosia A, Cavallo F, Massaia M.

J Cell Mol Med. 2010 Dec;14(12):2803-15. doi: 10.1111/j.1582-4934.2009.00926.x.

43.

Geriatric ward hospitalization reduced incidence delirium among older medical inpatients.

Bo M, Martini B, Ruatta C, Massaia M, Ricauda NA, Varetto A, Astengo M, Torta R.

Am J Geriatr Psychiatry. 2009 Sep;17(9):760-8.

PMID:
19705520
44.

Comprehensive assessment of the TCRBV repertoire in small T-cell samples by means of an improved and convenient multiplex PCR method.

Mariani S, Hwang SY, Foglietta M, Bonello L, Vitale C, Coscia M, Fiore F, Bruno B, Massaia M.

Exp Hematol. 2009 Jun;37(6):728-38. doi: 10.1016/j.exphem.2009.03.003.

PMID:
19463773
45.

Telomere length is an independent predictor of survival, treatment requirement and Richter's syndrome transformation in chronic lymphocytic leukemia.

Rossi D, Lobetti Bodoni C, Genuardi E, Monitillo L, Drandi D, Cerri M, Deambrogi C, Ricca I, Rocci A, Ferrero S, Bernocco E, Capello D, De Paoli L, Bergui L, Boi M, Omedè P, Massaia M, Tarella C, Passera R, Boccadoro M, Gaidano G, Ladetto M.

Leukemia. 2009 Jun;23(6):1062-72. doi: 10.1038/leu.2008.399. Epub 2009 Apr 2.

PMID:
19340005
46.

Efficacy of oxycodone/acetaminophen and codeine/acetaminophen vs. conventional therapy in elderly women with persistent, moderate to severe osteoarthritis-related pain.

Corsinovi L, Martinelli E, Fonte G, Astengo M, Sona A, Gatti A, Massaia M, Bo M, Zanocchi M, Michelis G, Isaia G, Molaschi M.

Arch Gerontol Geriatr. 2009 Nov-Dec;49(3):378-82. doi: 10.1016/j.archger.2008.12.003. Epub 2009 Jan 16.

47.

White-coat effect among older patients with suspected cognitive impairment: prevalence and clinical implications.

Bo M, Massaia M, Merlo C, Sona A, Canadè A, Fonte G.

Int J Geriatr Psychiatry. 2009 May;24(5):509-17. doi: 10.1002/gps.2145. Erratum in: Int J Geriatr Psychiatry. 2011 Jan;26(1):109. Mario, Bo [corrected to Bo, Mario]; Massimiliano, Massaia [corrected to Massaia, Massimiliano]; Chiara, Merlo [corrected to Merlo, Chiara]; Alessandro, Sona [corrected to Sona, Alessandro]; Antonella, Canadè [corrected to Canadè, Antonella]; Gianfranco,.

PMID:
18937278
48.

Low folate levels in the cognitive decline of elderly patients and the efficacy of folate as a treatment for improving memory deficits.

Fioravanti M, Ferrario E, Massaia M, Cappa G, Rivolta G, Grossi E, Buckley AE.

Arch Gerontol Geriatr. 1998 Jan-Feb;26(1):1-13.

PMID:
18653121
49.

CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib.

Piva R, Ruggeri B, Williams M, Costa G, Tamagno I, Ferrero D, Giai V, Coscia M, Peola S, Massaia M, Pezzoni G, Allievi C, Pescalli N, Cassin M, di Giovine S, Nicoli P, de Feudis P, Strepponi I, Roato I, Ferracini R, Bussolati B, Camussi G, Jones-Bolin S, Hunter K, Zhao H, Neri A, Palumbo A, Berkers C, Ovaa H, Bernareggi A, Inghirami G.

Blood. 2008 Mar 1;111(5):2765-75. Epub 2007 Dec 5.

50.

Phase I/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient-specific tumour idiotype protein or idiotype (VDJ)-derived class I-restricted peptides.

Curti A, Tosi P, Comoli P, Terragna C, Ferri E, Cellini C, Massaia M, D'Addio A, Giudice V, Di Bello C, Cavo M, Conte R, Gugliotta G, Baccarani M, Lemoli RM.

Br J Haematol. 2007 Nov;139(3):415-24.

PMID:
17910631

Supplemental Content

Loading ...
Support Center